SGN-40 is a therapeutic antibody targeting CD40, which induces potent anti-lymphoma activities via direct apoptotic signalling cells and by cell-mediated cytotoxicity. Here we show antibody-dependent cellular phagocytosis (ADCP) by macrophages to contribute significantly to the therapeutic activities and that the antitumour effects of SGN-40 depend on Fc interactions.
CD40 is a member of the tumour necrosis factor (TNF) receptor superfamily and is expressed predominantly on haematopoietic cells, including B-cells, dendritic cells, monocytes, macrophages, activated B-cells and CD8 þ T-cells (reviewed in van Kooten and Banchereau (2000) ). In lymphoid malignancies, CD40 is present on B-cell precursor acute lymphoblastic leukaemia (ALL (Uckun et al, 1990) ), non-Hodgkin's lymphoma (NHL (Uckun et al, 1990) ), Hodgkin's lymphoma (HL (O'Grady et al, 1994) ) and multiple myeloma (MM (Westendorf et al, 1994) ).
The humanised monoclonal antibody targeting CD40 (SGN-40) induces potent antitumour effects when tested on CD40-positive tumour cell lines representing a variety of haematologic malignancies (Tai et al, 2004; Law et al, 2005) . The mechanisms mediating the antitumour activity of SGN-40 include direct cytotoxic signalling, inducing caspase-3 activation and apoptosis of tumour cells (Law et al, 2005; Tai et al, 2005) and natural killer (NK) cell-mediated ADCC. Both, direct cell killing and NK cellmediated ADCC are enhanced by antibody crosslinking (Law et al, 2005) when tested in vitro. However, the mechanism involved in mediating anti-lymphoma activity of SGN-40 in vivo remained to be investigated.
The ability of several human IgG1-type therapeutic antibodies to engage human effector cells varies significantly, depending on the target antigen and tumour type, and variable degrees of tumour cell death induced by NK cells, neutrophils and macrophages were reported for anti-CD19, -20 and -70 antibodies (reviewed in Tedder et al (2006) ). Here we show for the first time that macrophages contribute significantly to the antitumour effects of SGN-40 when tested in models of human lymphoma. In addition, a mutant form of , lacked therapeutic activity when tested in vitro and in mice implanted with B-cell lymphomas. The important role of macrophages in mediating therapeutic activity described here may help to guide the clinical development of SGN-40 for the treatment of B-cell malignancies.
MATERIALS AND METHODS

Cells and reagents
The CD40-positive lymphoma cell lines Ramos (NHL, Burkitt's lymphoma) and WIL2-S (B-cell lymphoma) were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). The CD40-negative cell line L540cy was kindly provided by Dr Phil Thorpe (University of Texas, Southwestern Medical School, Dallas, TX, USA). Cells were grown in RPMI (Life Technologies Inc., Gaithersburg, MD, USA) supplemented with 20% fetal bovine serum (FBS).
Construction and expression of SGN-40G1v1 variant antibody and Fcc receptors
The anti-CD40 variant containing the mutations, E233P: L234V:L235A (Armour et al, 1999 ) (SGN-40G1v1) was generated using the Quikchange Site-Directed Mutagenesis system (Stratagene, La Jolla, CA, USA). The SGN-40 variant heavy chain and SGN-40 light chain were each cloned into the expression vector pDEF38 (Running Deer and Allison, 2004) downstream of the CHEF EF-1a promoter and stably expressed in CHO-DG44 (Urlaub et al, 1986) 
Antibody-dependent cellular phagocytosis assay
The assay was performed as described earlier (McEarchern et al, 2007) . Briefly, after labelling of CD40-positive target cells (Ramos), cells were pre-coated with SGN-40 or SGN-40G1v1 and incubated with monocyte-derived macrophages. The purity of the macrophage preparations were routinely 495% (data not shown).
Xenograft models and effector cell ablation and IHC analysis
Tumour bearing CB-17/lcr SCID mice were depleted of effector cells by using anti-asialo-GM 1 (1.25 mg kg À1 , neutrophils) and anti-Gr-1 (4 mg kg À1 , NK cells) clodronate encapsuled liposomes (CEL, macrophage), as described earlier . For IHC analysis, liver and spleen sections were stained with an antimouse F4/80 (macrophage marker) (AbD Serotec, Oxford, UK) using the Bondmax autostainer (Leica Microsystems Inc., Bannockburn, IL, USA) with an alkaline phosphatase-fast red detection kit. Mice were monitored at least twice per week and were sacrificed when they exhibited signs of disease, including weight loss of 15 -20%, hunched posture, lethargy, cranial swelling or dehydration. Statistical analysis was conducted using the log-rank test with the Graphpad Prism Software Package version 4.01 (Graphpad). All animal experiments were performed according to the guidelines of the Institutional Animal Care and Use Committee (IACUC).
RESULTS AND DISCUSSION
To study the contributions of Fc-receptor interactions to the antitumour activity of SGN-40, we constructed an Fc variant form (E) FACS analysis of spleen from NK cell-depleted mice using anti-DX5 antibody, or peripheral blood from neutrophil-depleted mice, using an anti-CD11b antibody. The right panels display IHC analysis of liver tissues isolated from macrophage-depleted mice using an anti-mouse-F4/80 antibody. (SGN-40G1v1) . When introduced to other therapeutic MAbs of the IgG1 isotype, these changes resulted in abolished Fc-receptor interactions (Armour et al, 1999) . As expected, no changes in the ability of SGN-40 and SGN-40G1v1 to bind to CD40 were observed ( Figure 1A) . However, competition binding assays with cells expressing human or mouse CD16 (FcgRIII) and CD64 (FcgRI) confirmed that SGN-40G1v1 lacked binding affinity to Fc receptors ( Figure 1B) . For SGN-40, weaker binding to mouse relative to human CD64 (FcgR1) and lack of binding to mouse CD16 (FcgRIII) were also noticed. Although Fcg-receptor interactions are essential for effector cell activation, no direct correlation between binding affinities of therapeutic antibodies and activation of effector cells were reported (Richards et al, 2008) , because these responses are ultimately regulated by the balance between activating and inhibitory signals delivered through Fcg receptors. Therefore, the differences in binding affinity of SGN-40 between Fcg-RI þ III are not predictive for antitumour activities in vivo.
To determine the levels of antibody-dependent cellular phagocytosis (ADCP) engagement, SGN-40 and SGN-40G1v1 were incubated in presence of primary human monocytic cells and tested for their ability to induce phagocytosis of CD40 þ Ramos (Burkitt's lymphoma, Figures 1C and D) and WIL2-S cells (B-cell lymphoma, Figure 1D ) by macrophages. Although SGN-40 induced robust ADCP, SGN-40G1v1 was devoid of detectable ADCP activity, showing that Fc -Fcg-receptor interactions are necessary for phagocytic uptake of target lymphoma cells ( Figure 1D ). These studies show that Fc-dependent ADCP may represent an important mechanism by which SGN-40 induces anti-lymphoma effects.
To investigate the relevance of Fc -FcgR interactions for overall therapeutic activity, we compared survival of tumour bearing mice treated with either SGN-40 or SGN-40G1v1. In contrast to SGN-40, SGN-40G1v1 did not delay disease progression relative to untreated mice ( Figure 1E ). These findings indicate that all mechanisms contributing to anti-lymphoma activities by SGN-40 are dependent on Fc interactions in this NHL model, including direct apoptotic signalling in tumour cells. Next, we were interested to identify the identity of the effector cells mediating the antitumour activity of SGN-40 in vivo. For this purpose, tumour-bearing mice were selectively depleted of either NK cells (Figure 2A ), neutrophils ( Figure 2B ), macrophages ( Figure 2C ) or all three cell types combined ( Figure 2D ). Although the lack of NK cells and neutrophils did not significantly affect the antitumour activity of SGN-40, depletion of macrophages, either alone or combined with NK and neutrophil cells, resulted in decreased survival of tumour-bearing mice compared with non-effector cell ablated animals ( Figures 2C and D, P ¼ 0.0016 and 0 .0004, respectively). These findings are in agreement with an earlier report showing potent antitumour activity of SGN-40 in SCIDbeige mice, which display impaired NK cell functions (Law et al, 2005) . Antitumour activity was evident in macrophage ablated mice ( Figure 2C ), suggesting that non-macrophage-dependent mechanisms may contribute to the in vivo activity in this model, including direct apoptotic signalling in tumour cells. The degree of effector cell depletion was monitored by FACS or IHC analysis ( Figure 2E ). Robust target effector cell depletion was confirmed by flow cytometric analysis of splenocytes (NK cells, anti-DX5), peripheral blood (neutrophils, anti-CD11b) or by F4/80-IHC staining (macrophages) in liver sections.
In humans, macrophages express all three Fcg receptors, whereas neutrophils and NK cells express predominantly FcgRII and FcgRIII (Koene et al, 1997) . Sequence nucleotide polymorphisms within the FCGR2 and FCGR3 loci in humans alter their binding affinities to IgG1 Mabs, and ultimately impact on downstream effector cell engagement of therapeutic Mabs such as the anti-CD20 antibody Rituximab (Weng and Levy, 2003) . In addition, the contributions of effector cells to antitumour effects of therapeutic MAbs were shown to vary between tumour types. For example, FcgR II þ III single nucleotide polymorphisms (SNPs) correlated with therapeutic activity of rituximab in NHL, but not in CLL patients (Cartron et al, 2002; Weng and Levy, 2003; Farag et al, 2004) . Combined, these findings suggest that the analysis of patient Fcg-receptor polymorphisms and comparison with clinical response rates may provide important information regarding the mechanism of action employed by SGN-40 in different heme-malignancies, including NHL and MM. Importantly, the chemotherapy agents used for the treatment of NHL were shown to interfere differentially with macrophage functions (Marcus and Hagenbeek, 2007) . Given the important role of macrophages in mediating the therapeutic activity of SGN-40 described in this report, it is tempting to speculate that combining SGN-40 with therapeutic agents that enhance macrophage activities, including Revlimid in MM indications, may be beneficial.
